Emerging evidence indicates that maternal medical risk during pregnancy, such as gestational diabetes mellitus (GDM), preeclampsia, and obesity, predisposes the offspring to suboptimal development. However, the underlying biological/epigenetic mechanism in utero is still unknown. The current pilot study (N = 50) compared the levels of global methylation in the placenta and umbilical cord blood among women with and without each risk condition (GDM, preeclampsia, and obesity) and explored whether the levels of global methylation were associated with fetal/infant growth. Results show that global methylation levels in the placenta were lower in patients with gestational diabetes (P =.003) and preeclampsia (P =.05) but higher with obesity (P =.01). Suggestive negative associations were found between global methylation level in the placenta and infant body length and head circumference. While preliminary, it is possible that the placenta tissue, but not umbilical cord blood, may be epigenetically programmed by maternal GDM, preeclampsia, and obesity to carry out its own specific functions that influence fetal growth.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalReproductive Sciences
Issue number1
StatePublished - Jan 2014


  • birth outcomes
  • fetal programming
  • gestational diabetes mellitus
  • global methylation
  • obesity
  • placenta
  • preeclampsia
  • umbilical cord blood


Dive into the research topics of 'Global methylation in the placenta and umbilical cord blood from pregnancies with maternal gestational diabetes, preeclampsia, and obesity'. Together they form a unique fingerprint.

Cite this